Key result
Six weeks of rivaroxaban achieves ~42% LA thrombus resolution in patients with nonvalvular AF.
Why the study?
Does rivaroxaban improve LA/LAA thrombus resolution in patients with nonvalvular atrial fibrillation or flutter compared to standard-of-care anticoagulation?
Does rivaroxaban improve LA/LAA thrombus resolution in patients with nonvalvular atrial fibrillation or flutter compared to standard-of-care anticoagulation?
Rivaroxaban treatment for 6 weeks resulted in a 41.5% resolution rate of LA/LAA thrombi in patients with nonvalvular AF or flutter, suggesting it as a potential treatment option.
No takes yet. Share an insight, caveat, or question.
Modest LA thrombus resolution with rivaroxaban warrants caution against routine use; leaves open comparative efficacy versus standard anticoagulation in randomized trials.
Lip et al. (2016) studied this question. Rivaroxaban treatment for 6 weeks resulted in a left atrial thrombus resolution rate of 41.5% (95% CI 28.1%-55.9%) in patients with nonvalvular atrial fibrillation or flutter.